Stock Evaluator: Dr. Reddy's Laboratories Limited (RDY)

Dr. Reddy's Laboratories Limited RDY

$11.85 0.02 0.17%
July 31, 2026 4:00:02 PM EST November 10, 2021 Volume: 3,009,769
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Commentary & Analysis


Financial Summary

Share Statistics RDY Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $9,965.6 $569.9 77%
Shares Out (Mil) 8.8 44.8 19%
Institutional Ownership 70.9% 84.6% 43%
Float (Mil) 600.0 45.1 87%
Beta 0.26 0.67 15%
Avg Daily Volume (000s) 3,182 294 88%
Price Change
(52-week)
(19.9%) 65.2% 31%
Growth RDY Industry
Median
Percentile
(All Stocks)
Sales (5yr) 6.7% 6.7% 44%
Net Income (5yr) 14.2% (2.0%) 61%
EPS (5yr) 14.1% 14.9% 54
Dividends (5yr) 4.5% 0.0% 56%
Cash Flow (5yr) (43.0%) (14.9%) 10%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials RDY Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $3,503 $230 69%
Net Income (TTM) (Mil) $350 ($11) 75%
EPS (TTM) $0.420 ($0.600) 52%
Operating Cash Flow (TTM) (Mil) $436 ($6) 70%
Net Cash Flow (TTM) (Mil) $28 $4 66%
Long-Term Debt (Q1) (Mil) $126 $7 46%
Enterprise Value (Q1) (Mil) $10,089 $493 74%
Valuation RDY Industry
Median
Percentile
(All Stocks)
P/B 2.43 2.89 58%
P/E 28.2 20.6 66%
Dividend Yield 0.7% 0.0% 64%
PEG (5yr hist) 2.0 1.1 67%
Ratios RDY Industry
Median
Percentile
(All Stocks)
Gross Margin 50.2% 65.9% 62%
Net Margin 10.0% (0.2%) 63%
ROA 5.8% (25.5%) 76%
ROE 8.6% (21.4%) 53%
Liabilities to Assets 32.8% 35.5% 24%
F-Score 5 3 51%

Dr. Reddy's Laboratories Limited did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors